Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Nivolumab (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 29 May 2024 Status changed from active, no longer recruiting to completed.
- 07 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.